Drugs & TargetsFree FDA approves Lynparza + bevacizumab as maintenance treatment for ovarian, fallopian tube, or primary peritoneal cancers May 15, 2020Vol.46 No.20
Drugs & TargetsFree FDA approves Tabrecta, first targeted therapy to treat metastatic NSCLC May 08, 2020Vol.46 No.19
Drugs & TargetsFree FDA approves daratumumab and hyaluronidase-fihj for multiple myeloma May 08, 2020Vol.46 No.19
Drugs & TargetsFree Caris Life Sciences submits two PMA applications to FDA for whole exome and whole transcriptome sequencing May 08, 2020Vol.46 No.19
Drugs & TargetsFree FDA approves GSK’s PARP inhibitor Zejula for first-line maintenance of advanced ovarian cancer May 01, 2020Vol.46 No.18
Drugs & TargetsFree FDA grants accelerated approval to new dosing regimen for Keytruda May 01, 2020Vol.46 No.18
Drugs & TargetsFree FDA grants Mobocertinib Breakthrough Therapy Designation in NSCLC designation May 01, 2020Vol.46 No.18
Drugs & TargetsFree FDA grants accelerated approval for Trodelvy in previously-treated metastatic TNBC April 24, 2020Vol.46 No.17
